BioPharma Resources

Drug Trial Radar · NCT01925209

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis

Last checked: Nov 19, 2026Latest source record: Aug 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Sep 26, 2013

Primary completion

Jan 6, 2016

Study completion Jan 6, 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 36 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).

Conditions

  • Sporadic Inclusion Body Myositis

Interventions

  • BYM338/bimagrumabDrug

    BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

  • PlaceboDrug

    Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52Time frame: Baseline, Week 52

Locations

38 sites in 10 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Orange, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Kansas City, Kansas

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    St Leonards, New South Wales, Australia

  • Novartis Investigative Site

    Cauldfield, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Rome, Lazio, Italy

  • Novartis Investigative Site

    Messina, ME, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Padova, PD, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Kumamoto, Kumamoto, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, Japan

  • Novartis Investigative Site

    Osaka, Osaka, Japan

  • Novartis Investigative Site

    Tokushima, Tokushima, Japan

  • Novartis Investigative Site

    Kodaira, Tokyo, Japan

  • Novartis Investigative Site

    Wakayama, Wakayama, Japan

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Leiden, Netherlands

  • Novartis Investigative Site

    Zurich, Switzerland

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Newcastle upon Tyne, United Kingdom

  • Novartis Investigative Site

    Salford, Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.